http://orcid.org/0000-0002-5938-7495
References
- Schmiegelow K, Nielsen SN, Frandsen TL, et al. Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol. 2014;36(7):503–517.
- Zaza G, Cheok M, Krynetskaia N, et al. Thiopurine pathway. Pharmacogenet Genom. 2010;20(9):573.
- Bhatia S, Landier W, Shangguan M, et al. Nonadherence to oral mercaptopurine and risk of relapse in hispanic and non-hispanic white children with acute lymphoblastic leukemia: a report from the children’s oncology group. J Clin Oncol . 2012;30(17):2094–2101.
- Gerich ME, Quiros JA, Marcin JP, et al. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. J Crohns Colitis. 2010;4(5):546–552.
- Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(2):363–369.
- Leung Y, Sparrow MP, Schwartz M, et al. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis. 2009;3(3):162–167.
- Brackett J, Schafer ES, Bernhardt MB. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism. Pediatr Blood Cancer. 2013; 10:1–4.
- Giamanco NM, Cunningham BS, Klein LS, et al. Allopurinol use during maintenance therapy for acute lymphoblastic leukemia avoids mercaptopurine-related hepatotoxicity. J Pediatr Hematol Oncol. 2016;38(2):147–151.
- Angiolillo A, Schore R, Devidas M, et al. Intensification of oral methotrexate is not superior to standard methotrexate dosing during maintenance in children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): a report from Children’s Oncology Group (COG) study AALL0932. Blood. 2017; 130:140.
- Salzer WL, Burke MJ, Devidas M, et al. Triple intrathecal therapy (Methotrexate/Hydrocortisone/Cytarabine) does not improve disease-free survival versus intrathecal methotrexate alone in children with high risk b-lymphoblastic leukemia: results of children’s oncology group study AALL1131. Blood. 2018;132(Supplement 1):35.